Lifestyle Modifications may enhance TNF Inhibitors in axSpA

Anifrolumab shows long-term promise in patients with lupus Researchers report positive results from the first placebo-

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Anifrolumab shows long-term promise in patients with lupus Researchers report positive results from the first placebo-controlled long-term trial of anifrolumab—a human monoclonal antibody that targets the type I IFN receptor—in patients with lupus. https://t.co/IlgEUKkMOv https://t.co/kpSt61d5Qx
Links
https://bit.ly/3EoB6Dx

Effect of voclosporin in class V lupus nephritis Dr. Yusof ( @Yuz6Yusof) discusses abstract 0355 presented at #ACR22.

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Effect of voclosporin in class V lupus nephritis Dr. Yusof ( @Yuz6Yusof) discusses abstract 0355 presented at #ACR22. Abstract 0355: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study https://t.co/sH04dhBskS https://t.co/mUOrJKdYBF
Links
https://bit.ly/3GqHf4I

JAK vs TNF inhibitor Infections in RA Dr. David Liew ( @drdavidliew) discusses abstract 0302 at #ACR22 Convergence. A

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
JAK vs TNF inhibitor Infections in RA Dr. David Liew ( @drdavidliew) discusses abstract 0302 at #ACR22 Convergence. Abstract 0302: Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis https://t.co/ipD5ON7BJ7 https://t.co/rRD5wqHhFk
Links
https://bit.ly/3XsRCLB

Retrospective review of 265 ILD pts - 9.8% were ANCA positive (PR3, MPO). ANCA- oft called IPF. ANCA+ CTD-ILD and 65% ev

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Retrospective review of 265 ILD pts - 9.8% were ANCA positive (PR3, MPO). ANCA- oft called IPF. ANCA+ CTD-ILD and 65% evolved into AAV (29% AAV follwed ILD Dx). No lung diff betw Pos v Neg pts, but ANCA+ had more drugs, hosp. #ACR22 https://t.co/X6UfiawfmW https://t.co/BZpTsjYAFW
Links
https://bit.ly/3EMc8zu

Breakthrough COVID infection in SLE during Omicron era Dr. Yusof ( @Yuz6Yusof) talks with Dr. Amit Saxena about abstr

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Breakthrough COVID infection in SLE during Omicron era Dr. Yusof ( @Yuz6Yusof) talks with Dr. Amit Saxena about abstract #2081 at #ACR22 Abstract 2081: COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients.... https://t.co/0OFcHK2PLj https://t.co/2ULOfSZUqU
Links
https://bit.ly/3Goj6M9

Opioids and Health Care Utilization in PsA and AS Dr Aurelie Najm ( @AurelieRheumo) discusses Abstract 0402 presented

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Opioids and Health Care Utilization in PsA and AS Dr Aurelie Najm ( @AurelieRheumo) discusses Abstract 0402 presented at #ACR22. Abstract 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS https://t.co/trruZGyIVf https://t.co/8kj9vpKPlD
Links
https://bit.ly/3TMFeTp
Subscribe to
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×